BR112023020341A2 - Anticorpo multiespecífico, composição farmacêutica, método para tratar uma doença relacionada à expressão de bcma e anticorpo de ligação a bcma - Google Patents
Anticorpo multiespecífico, composição farmacêutica, método para tratar uma doença relacionada à expressão de bcma e anticorpo de ligação a bcmaInfo
- Publication number
- BR112023020341A2 BR112023020341A2 BR112023020341A BR112023020341A BR112023020341A2 BR 112023020341 A2 BR112023020341 A2 BR 112023020341A2 BR 112023020341 A BR112023020341 A BR 112023020341A BR 112023020341 A BR112023020341 A BR 112023020341A BR 112023020341 A2 BR112023020341 A2 BR 112023020341A2
- Authority
- BR
- Brazil
- Prior art keywords
- bcma
- treating
- pharmaceutical composition
- disease related
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110405638 | 2021-04-15 | ||
| PCT/CN2022/086842 WO2022218380A1 (zh) | 2021-04-15 | 2022-04-14 | 靶向bcma的多特异性抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023020341A2 true BR112023020341A2 (pt) | 2024-02-06 |
Family
ID=83640152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023020341A BR112023020341A2 (pt) | 2021-04-15 | 2022-04-14 | Anticorpo multiespecífico, composição farmacêutica, método para tratar uma doença relacionada à expressão de bcma e anticorpo de ligação a bcma |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240182592A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4324853A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024516098A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230170721A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117062840A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022256638A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023020341A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3214012A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307308A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023011923A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202304963A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022218380A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4201960A4 (en) * | 2020-08-20 | 2024-09-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | BCMA-BINDING SINGLE MOLECULE WITH VARIABLE DOMAIN AND ANTIGEN-BINDING MOLECULE |
| WO2022037527A1 (zh) * | 2020-08-20 | 2022-02-24 | 正大天晴药业集团股份有限公司 | 结合bcma的单可变结构域及抗原结合分子 |
| JP2026513451A (ja) * | 2023-04-24 | 2026-04-27 | 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 | c-Metを標的とする多重特異性抗体 |
| CN119119246B (zh) * | 2024-06-26 | 2025-10-10 | 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) | 一种抗非洲猪瘟病毒k205r蛋白的纳米抗体及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013246443B2 (en) * | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| PL3177643T3 (pl) * | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T |
| TWI811023B (zh) * | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| PL3896091T3 (pl) | 2016-08-10 | 2024-04-29 | Legend Biotech Ireland Limited | Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania |
| US11124577B2 (en) * | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| CN110891971B (zh) * | 2017-06-20 | 2024-01-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| KR20200142525A (ko) | 2018-04-05 | 2020-12-22 | 노파르티스 아게 | 암에 대한 삼중특이성 결합 분자 및 이의 용도 |
| BR112021008486A2 (pt) * | 2018-11-01 | 2021-10-26 | Shandong New Time Pharmaceutical Co., Ltd | Anticorpo biespecífico e seu uso |
| CN110551221B (zh) * | 2019-07-02 | 2021-03-05 | 广州爱思迈生物医药科技有限公司 | 一种双特异性抗体及其制备方法与应用 |
| CN112574308A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 靶向bcma的抗体、双特异性抗体及其用途 |
| EP4201960A4 (en) * | 2020-08-20 | 2024-09-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | BCMA-BINDING SINGLE MOLECULE WITH VARIABLE DOMAIN AND ANTIGEN-BINDING MOLECULE |
| WO2022037527A1 (zh) * | 2020-08-20 | 2022-02-24 | 正大天晴药业集团股份有限公司 | 结合bcma的单可变结构域及抗原结合分子 |
| CN112794916B (zh) * | 2021-04-08 | 2021-08-10 | 正大天晴药业集团南京顺欣制药有限公司 | 三特异性抗原结合构建体及构建方法和应用 |
-
2022
- 2022-04-14 KR KR1020237038699A patent/KR20230170721A/ko active Pending
- 2022-04-14 JP JP2023561864A patent/JP2024516098A/ja active Pending
- 2022-04-14 CA CA3214012A patent/CA3214012A1/en active Pending
- 2022-04-14 MX MX2023011923A patent/MX2023011923A/es unknown
- 2022-04-14 WO PCT/CN2022/086842 patent/WO2022218380A1/zh not_active Ceased
- 2022-04-14 US US18/285,511 patent/US20240182592A1/en active Pending
- 2022-04-14 AU AU2022256638A patent/AU2022256638A1/en active Pending
- 2022-04-14 IL IL307308A patent/IL307308A/en unknown
- 2022-04-14 TW TW111114188A patent/TW202304963A/zh unknown
- 2022-04-14 EP EP22787602.6A patent/EP4324853A4/en active Pending
- 2022-04-14 BR BR112023020341A patent/BR112023020341A2/pt unknown
- 2022-04-14 CN CN202280022841.5A patent/CN117062840A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230170721A (ko) | 2023-12-19 |
| EP4324853A1 (en) | 2024-02-21 |
| CN117062840A (zh) | 2023-11-14 |
| MX2023011923A (es) | 2023-10-23 |
| JP2024516098A (ja) | 2024-04-12 |
| WO2022218380A1 (zh) | 2022-10-20 |
| IL307308A (en) | 2023-11-01 |
| AU2022256638A1 (en) | 2023-11-09 |
| CA3214012A1 (en) | 2022-10-20 |
| TW202304963A (zh) | 2023-02-01 |
| US20240182592A1 (en) | 2024-06-06 |
| EP4324853A4 (en) | 2025-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
| BR112018075479A2 (pt) | portadores híbridos para carga de ácido nucleico | |
| BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| MX2021014952A (es) | Molecula de union especifica para cd73 y uso de la molecula de union. | |
| CL2016003324A1 (es) | Construcciones de anticuerpos multiespecificos. | |
| BR112022008192A2 (pt) | Queratina bd-4, sua preparação e composições farmacêuticas e uso | |
| BR112022004972A2 (pt) | Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso | |
| BR112015008708A2 (pt) | composição para clivagem de dna alvo compreendendo um rna guia específico para o dna alvo e ácido nucleico que codifica proteína cas ou proteína cas e uso da mesma | |
| BR112016008593A8 (pt) | composto, composição farmacêutica, método de regulação de transcrição gênica em uma célula, uso de um composto e método de inibição de reconhecimento mediado por bromodomínio de uma região de acetil lisina de uma proteína | |
| BR112016030424A2 (pt) | construções de anticorpo multiespecíficas | |
| BR112017018728A2 (pt) | sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada | |
| MX2022000586A (es) | Anticuerpos anti-tigit y aplicacion de los mismos. | |
| MX2023011923A (es) | Anticuerpos multiespecificos dirigidos al antigeno de maduracion de celulas b. | |
| BR112015014372A2 (pt) | inibidores de autotaxina | |
| BR112021005777A2 (pt) | Produtos e composições | |
| CL2018000622A1 (es) | Acetamida tienodiazepinas de triazol y sus usos relacionados. | |
| BRPI0921096A8 (pt) | Composições e métodos para inibir a expressão dos genes de fator vii | |
| BR112022017174A2 (pt) | Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor | |
| BR112019005129A2 (pt) | anticorpos anti-pd-1 | |
| BR112012009432A2 (pt) | anticorpo anti-hsv | |
| BR112013017363A2 (pt) | biblioteca de alphabody de cadeia única, mistura de bibliotecas de alphabody, ácido nucleico ou biblioteca de vetor, biblioteca de células hospedeiras, uso de uma biblioteca de alphabody de cadeia única, método para a produção de uma biblioteca de alphabody de cadeia única, método para a produção de um ou mais polipeptídeos de alphabody de cadeia única, polipeptíceo de alphabody de cadeia única, ácido nucleico, vetor e célula hospedeira | |
| BR112022007948A2 (pt) | Queratina bd-3, molécula de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, método para preparar a queratina bd-3, e, uso da queratina bd-3 ou da molécula de ácido nucleico ou do vetor de expressão ou da célula hospedeira ou da composição farmacêutica | |
| CL2025003136A1 (es) | Anticuerpo multiespecífico dirigido a c-met. | |
| CO2023016037A2 (es) | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos | |
| BR112022004594A2 (pt) | Receptor de reconhecimento de antígeno, célula, molécula de ácido nucleico, vetor, célula hospedeira, composição, métodos e kit |